VEA
Virtus ETF Advisers Portfolio holdings
AUM
$75.7M
1-Year Return
23.01%
This Quarter Return
+9.34%
1 Year Return
+23.01%
3 Year Return
+79.79%
5 Year Return
+153.94%
10 Year Return
–
AUM
$612M
AUM Growth
+$115M
(+23%)
Cap. Flow
+$92.1M
Cap. Flow
% of AUM
15.06%
Top 10 Holdings %
Top 10 Hldgs %
8.98%
Holding
532
New
97
Increased
238
Reduced
88
Closed
80
Top Buys
| 1 |
Telecom Argentina
TEO
|
$2.3M |
| 2 |
Methanex
MEOH
|
$1.47M |
| 3 |
The GEO Group
GEO
|
$1.43M |
| 4 |
EQM
EQM Midstream Partners, LP
EQM
|
$1.42M |
| 5 |
Vale
VALE
|
$1.35M |
Top Sells
| 1 |
Oxford Square Capital
OXSQ
|
$2.69M |
| 2 |
MPLX
MPLX
|
$1.51M |
| 3 |
MDCO
Medicines Co
MDCO
|
$982K |
| 4 |
Gladstone Investment Corp
GAIN
|
$839K |
| 5 |
CELG
Celgene Corp
CELG
|
$712K |
Sector Composition
| 1 | Financials | 20.46% |
| 2 | Real Estate | 16.88% |
| 3 | Energy | 14.34% |
| 4 | Healthcare | 10.85% |
| 5 | Materials | 9.71% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
BLUE
251
DELISTED
bluebird bio
BLUE
| $403K | 0.07% |
355
+189
| +114% | +$215K |
|
252
Rhythm Pharmaceuticals
RYTM
$6.78B
| $401K | 0.07% |
17,450
+6,142
| +54% | +$141K |
|
|
TVRD
253
Tvardi Therapeutics, Inc. Common Stock
TVRD
$292M
| $401K | 0.07% |
691
+329
| +91% | +$191K |
|
254
uniQure
QURE
$985M
| $399K | 0.07% |
5,561
+2,085
| +60% | +$150K |
|
255
Arvinas
ARVN
$575M
| $398K | 0.07% |
9,698
-2,506
| -21% | -$103K |
|
|
ARNA
256
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $398K | 0.07% |
8,758
+4,174
| +91% | +$190K |
|
|
DCPH
257
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $397K | 0.06% |
6,371
-5,422
| -46% | -$338K |
|
|
ACHN
258
DELISTED
Achillion Pharmaceuticals, Inc.
ACHN
| $397K | 0.06% |
65,813
-24,741
| -27% | -$149K |
|
259
BridgeBio Pharma
BBIO
$10.2B
| $396K | 0.06% |
+11,295
| New | +$396K |
|
260
Allogene Therapeutics
ALLO
$246M
| $395K | 0.06% |
15,214
+5,662
| +59% | +$147K |
|
261
Rigel Pharmaceuticals
RIGL
$742M
| $395K | 0.06% |
+18,474
| New | +$395K |
|
|
KDMN
262
DELISTED
Kadmon Holdings, Inc.
KDMN
| $395K | 0.06% |
+87,094
| New | +$395K |
|
263
Alaunos Therapeutics
TCRT
$4.27M
| $394K | 0.06% |
557
+234
| +72% | +$166K |
|
|
TCDA
264
DELISTED
Tricida, Inc. Common Stock
TCDA
| $394K | 0.06% |
10,444
+3,090
| +42% | +$117K |
|
265
Arrowhead Research
ARWR
$4.02B
| $393K | 0.06% |
6,196
-3,589
| -37% | -$228K |
|
266
Assembly Biosciences
ASMB
$183M
| $393K | 0.06% |
1,600
+146
| +10% | +$35.9K |
|
267
MeiraGTx Holdings
MGTX
$619M
| $392K | 0.06% |
19,596
+7,285
| +59% | +$146K |
|
|
AMRS
268
DELISTED
Amyris Inc.
AMRS
| $390K | 0.06% |
126,372
+62,090
| +97% | +$192K |
|
|
TBIO
269
DELISTED
Translate Bio, Inc. Common Stock
TBIO
| $388K | 0.06% |
+47,685
| New | +$388K |
|
270
Regenxbio
RGNX
$490M
| $387K | 0.06% |
9,436
+4,204
| +80% | +$172K |
|
271
XBiotech
XBIT
$89M
| $387K | 0.06% |
+20,735
| New | +$387K |
|
272
Madrigal Pharmaceuticals
MDGL
$9.65B
| $385K | 0.06% |
4,226
+1,626
| +63% | +$148K |
|
273
CRISPR Therapeutics
CRSP
$4.99B
| $384K | 0.06% |
+6,306
| New | +$384K |
|
274
Kura Oncology
KURA
$713M
| $383K | 0.06% |
27,872
+14,306
| +105% | +$197K |
|
275
Denali Therapeutics
DNLI
$2.26B
| $380K | 0.06% |
21,805
+8,311
| +62% | +$145K |
|